Tris Pharma to Present New Safety Data and Host Symposium at IASP 2024 World Congress on Pain

Tris Pharma, Inc., a biopharmaceutical company specializing in treatments for ADHD, pain, addiction, and neurological disorders, has announced a significant presentation at the upcoming International Association for the Study of Pain (IASP) World Congress on Pain, scheduled for August 5-9, 2024, in Amsterdam. The company will reveal data from its late-stage investigational pain therapy, cebranopadol, which has a unique mechanism of action.

Ketan Mehta, the founder and CEO of Tris Pharma, expressed his enthusiasm about the increased focus on developing new treatment options for individuals suffering from chronic pain. He emphasized the company's dedication to advancing cebranopadol, aiming to provide healthcare professionals with a reliable and safe pain management solution. Mehta highlighted the importance of engaging with the pain research community at IASP 2024 to share their latest findings.

Cebranopadol stands out as the first dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist being developed for moderate-to-severe pain relief. This dual-NMR agonist approach is promising because it mimics the body's natural pain modulation processes, combining the analgesic properties of both the NOP and MOP receptors. This synergy has the potential to offer effective pain relief with a strong safety profile. Tris Pharma plans to release new updates on their Phase 3 clinical trials for cebranopadol soon.

The company will also host a symposium at the congress, focusing on the innovative dual-NMR agonist mechanism. This symposium aims to address the limitations of current opioid treatments for moderate-to-severe pain and explore the potential benefits of this new approach. Leading scientists in pain research and development, including Dr. Charles E. Argoff from Albany Medical College, Dr. Roberto Ciccocioppo from the University of Camerino, and Dr. Jeffrey Gudin from the University of Miami Miller School of Medicine, will present their insights.

The symposium, titled "Break the Mold in Pain Biology: The Promise of a New Mechanism that May Overcome the Shortfalls of Current Moderate to Severe Pain Medications," will take place at the RAI Amsterdam Convention Centre on August 6, from 12:45 to 1:45 p.m. CEST. During the conference, Tris Pharma will be available at Booth #316 to provide additional information and discuss the data presented.

Cebranopadol, also known as TRN-228, is unique in its dual action on the NOP and MOP receptors. This mechanism not only aims to provide effective pain relief but also has the potential to reduce the risk of misuse and block drug-seeking behaviors associated with opioid use. The FDA has granted Fast Track Designation for cebranopadol in treating chronic low back pain, highlighting its potential to become a groundbreaking pain-relief therapy with less risk of dependence, addiction, or overdose compared to traditional opioids.

Tris Pharma is a privately held company dedicated to innovation in drug development, focusing on ADHD, pain, and neurological disorders, including addiction and central nervous system diseases. The company has a robust portfolio of ADHD treatments and a promising pipeline of new drug candidates.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!